Clinical trial
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
NCT03530696
Study timeline
Study start (actual)2018-12-06Date precision: day
Registry last updated2024-08-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Breast Cancerunresolved
Breast Cancerunresolved
Breast Cancer Stageunresolved
Recurrent Breast Cancerunresolved
Metastatic Breast Cancerunresolved
HER2 Positive Breast Carcinomaunresolved
Interventions
PalbociclibDRUG · verified · RxNorm: palbociclib
T-DM1DRUG
Sponsors & collaborators
University of Arizonalead sponsor
Pfizercollaborator
Mapped research locations
SeattleWashington, United States2PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1ClevelandOhio, United States1PortlandOregon, United States1AuroraColorado, United States1New HavenConnecticut, United States1TucsonArizona, United States1Chapel HillNorth Carolina, United States1AlbuquerqueNew Mexico, United States1MadisonWisconsin, United States1BuffaloNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03530696 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.